Frontiers in allergy最新文献

{"title":"Study protocol for a randomized double-blinded placebo-controlled trial on mepolizumab for patients with chronic rhinosinusitis with nasal polyps, NSAID exacerbated respiratory disease and asthma.","authors":"Annina Lyly, Johanna Sahlman, Karoliina Pajala, Maija Salminen, Saara Sillanpää, Jura Numminen, Tanzeela Hanif, Anu Laulajainen-Hongisto, Mika Mäkelä, Paula Kauppi, Iiris Kangasniemi, Markus Lilja, Sari Hammaren-Malmi, Paula Virkkula, Sanna Toppila-Salmi","doi":"10.3389/falgy.2025.1568081","DOIUrl":"10.3389/falgy.2025.1568081","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nose and paranasal sinuses that significantly impactshealth-related quality of life. Nonsteroidal anti-inflammatory drug (NSAID) -exacerbated respiratory disease (N-ERD) affects approximately one fifth of CRSwNP patients. N-ERD and asthma increase the risk of uncontrolled CRSwNP as measured by frequent sinus surgeries and rescue treatment. Compared to non-N-ERD patients, those with N-ERD also have higher risk of asthma exacerbations, severe allergic reactions, and anosmia. Mepolizumab is a humanized monoclonal anti-IL-5 antibody shown to be effective in treating severe eosinophilic asthma and CRSwNP. While evidence suggests that mepolizumab alleviates respiratory symptoms in N-ERD patients, placebo-controlled studies remain limited.</p><p><strong>Methods: </strong>The aim of this prospective randomized, placebo-controlled, multicenter study is to investigate whether mepolizumab reduces polyp size, symptom scores, and exacerbations more than placebo during the 16-week treatment period in patients with uncontrolled CRSwNP, N-ERD and asthma. Additionally, we will examine the effect of mepolizumab on drug dosage and lung and nasal function and evaluate predictive biomarkers.We will recruit 120 patients with N-ERD, nasal polyposis and asthma in three centers in Finland. Patients will be randomized into two 16-week treatment groups in 1:1 ratio (placebo or mepolizumab 100 mg every 4 weeks). The study lasts for 6 months, including recruitment visit 2-4 weeks before randomization. Participants will attend 6 visits, during four of which they will receive a subcutaneous injection of the study product. At each visit, patient-reported outcome tests, clinical examination, airway function tests, and nasal, blood, urine, and stool samples will be conducted.</p><p><strong>Discussion: </strong>The efficacy of the 16-week anti-IL-5-treatment in this severe patient group will be analyzed, as well as possible predictive biomarkers.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov ID NCT04823585. Registered on 28.3.2021.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1568081"},"PeriodicalIF":3.3,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between vaccination, viral antibodies, and asthma prevalence in the U.S.: insights from NHANES (1999-2020).","authors":"Zonghui Yang, Jia Guo, Manman Cheng, Youwen Zhang, Zhi Chen, Jie Wen, Fenglian Shan","doi":"10.3389/falgy.2025.1456934","DOIUrl":"10.3389/falgy.2025.1456934","url":null,"abstract":"<p><strong>Objective: </strong>This investigation aimed to explore the differences in asthma prevalence among various demographic groups in the U.S., focusing on factors related to vaccination and viral antibodies.</p><p><strong>Methods: </strong>The study analyzed data from 37,445 individuals collected through the National Health and Nutrition Examination Survey between 1998 and 2020. Employing weighted sampling methods, the analysis considered the stratification and clustering typical of the survey's design. It particularly examined how age, race, income, smoke, education, and gender factors influence both the prevalence and severity of asthma.</p><p><strong>Results: </strong>This study aims to elucidate disparities in asthma prevalence across the U.S. population by examining the roles of demographic characteristics and factors related to vaccination and viral antibodies. It revealed a significant correlation between asthma prevalence and patient demographics, including age, gender, income, smoke, education, and race. We found that asthma patients were mostly found in participants with lower economic level (2.7 vs. 2.87). Non-Hispanic black women age exhibited a higher likelihood of asthma, at 17.7%, compared to non-Hispanic whites and Mexican Americans. Asthma prevalence peaks between the ages of 20 and 30 and has shown a rising trend over the years. Regarding vaccinations, hepatitis A, hepatitis B, pneumococcal, and HPV vaccines were associated with an increased risk of asthma. Conversely, patients testing positive for hepatitis A virus and core hepatitis B virus antibodies demonstrated a lower prevalence of asthma. Additionally, asthmatic patients showed lower average measles virus and rubella antibodies levels, at 0.53 and 3.32, respectively, compared to non-asthmatic individuals. Notably, asthma incidence was lower in herpesvirus I-positive patients (OR: 0.895, CI, 0.809%-0.991%), while herpesvirus II-positive patients displayed a higher incidence of asthma (OR: 1.102, CI, 0.974%-1.246%).</p><p><strong>Conclusion: </strong>The study findings underscore the significant prevalence of asthma and its correlation with population demographics, vaccination rates, and serum viral antibodies. These results highlight the importance of implementing tailored public health interventions.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1456934"},"PeriodicalIF":3.3,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Gut microbiome features in pediatric food allergy: a scoping review.","authors":"Margherita Farnetano, Laura Carucci, Serena Coppola, Franca Oglio, Antonio Masino, Marica Cozzolino, Rita Nocerino, Roberto Berni Canani","doi":"10.3389/falgy.2025.1588779","DOIUrl":"https://doi.org/10.3389/falgy.2025.1588779","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/falgy.2024.1438252.].</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1588779"},"PeriodicalIF":3.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a <i>post hoc</i> analysis from the ANANKE study.","authors":"Luisa Brussino, Maria Aliani, Elena Altieri, Pietro Bracciale, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Laura Malerba, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Gianenrico Senna, Alessandra Vultaggio, Maria D'Amato","doi":"10.3389/falgy.2025.1501196","DOIUrl":"10.3389/falgy.2025.1501196","url":null,"abstract":"<p><strong>Introduction: </strong>Severe eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients present CRSwNP.</p><p><strong>Methods: </strong>This <i>post hoc</i> analysis of the ANANKE study (NCT04272463) reports data on the long-term effectiveness of benralizumab between SEA patients with and without CRSwNP (<i>N</i> = 86 and <i>N</i> = 75, respectively) treated for up to 96 weeks.</p><p><strong>Results: </strong>Before benralizumab initiation, CRSwNP patients displayed longer SEA duration, greater oral corticosteroid (OCS) use and blood eosinophil count. After 96 weeks of treatment, the annual exacerbation rate (AER) decreased in both groups, with CRSwNP patients achieving considerable reductions than No-CRSwNP patients (severe AER dropped by 100% and 95.6%, respectively). While lung function improvement was comparable at week 96, CRSwNP patients showed a faster response to benralizumab, with a rise of forced expiratory volume in 1 s (FEV₁) at 16 weeks that was maintained throughout the study. Median OCS daily dose decreased to 0.0 mg in both groups at 96 weeks, but benralizumab OCS-sparing effect was faster in CRSwNP patients (median OCS dose was 0.0 mg and 2.5 mg in CRSwNP and No-CRSwNP patients respectively, at 48 weeks). Although asthma control test (ACT) median scores were comparable, greater proportions of CRSwNP patients displayed well-controlled asthma (ACT ≥ 20) than No-CRSwNP patients at all time points.</p><p><strong>Discussion: </strong>These findings show benralizumab long-term effectiveness in SEA patients with and without CRSwNP, highlighting its superior and faster-acting benefits on asthma outcomes in presence of CRSwNP.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1501196"},"PeriodicalIF":3.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory symptoms, sensitisation and occupational exposure in the shrimp processing industry.","authors":"Fikirte Debebe Zegeye, Pål Graff, Miriam Grgic, Steen Mollerup, Anani Komlavi Afanou, Berit Elisabeth Bang, Karl-Christian Nordby, Anne Straumfors, Johanna Samulin Erdem","doi":"10.3389/falgy.2025.1520576","DOIUrl":"10.3389/falgy.2025.1520576","url":null,"abstract":"<p><strong>Introduction: </strong>Shellfish processing workers are highly susceptible to respiratory illnesses such as allergies and asthma. This study examined respiratory symptoms and biomarkers of allergy and asthma in Norwegian shrimp processing plant workers and evaluated allergenic and irritant protein exposures in the workplace.</p><p><strong>Material and methods: </strong>The study included 35 shrimp processing workers and 21 controls. Respiratory symptoms were assessed via questionnaire; blood samples were analysed for allergy and asthma biomarkers and specific IgE levels. Air samples were analysed for protein levels and composition.</p><p><strong>Results: </strong>Shrimp processing workers had four to five times higher odds of reporting acute upper and chronic lower respiratory symptoms than the controls. They also had significantly higher plasma levels of IL4, CCL20, CSF2 and MMP12, with 11% of the exposed workers showing elevated levels of shrimp and crab specific IgE. Furthermore, exposed workers showed increased plasma levels of SFTPD and CHI3L1 post-shift. The median total protein exposure was 6 µg/m³, with peaks up to 66 µg/m³ in the cooking and peeling department. Total protein levels were correlated with CCL20, IL13, and basophil counts. Ninety-five shrimp proteins were identified, including seven known and eight potential allergens. Tropomyosin levels were generally high, particularly in the cooking and peeling department.</p><p><strong>Conclusion: </strong>Shrimp workers had a higher prevalence of respiratory symptoms and biomarkers of allergy and asthma. The work environment contained tropomyosin and other allergenic proteins as well as irritants, highlighting the need for protective measures, especially in the cooking and peeling departments.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1520576"},"PeriodicalIF":3.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food allergen introduction practices and parent/caregiver attitudes based on family history of food allergy.","authors":"Hunter G Smith, Sai Nimmagadda, Ruchi S Gupta, Christopher M Warren","doi":"10.3389/falgy.2025.1562667","DOIUrl":"10.3389/falgy.2025.1562667","url":null,"abstract":"<p><strong>Background: </strong>The National Institute of Allergy and Infectious Disease (NIAID) addendum guidelines for primary prevention of peanut allergy1 provide recommendations regarding peanut introduction, and a recent consensus statement highlighted the importance of timely introduction of other commonly allergenic solids, and the role of family history as a risk factor.2ObjectiveTo determine whether children in households with a food allergic parent/caregiver or sibling have different rates of being fed commonly allergenic solids during the first year of life than children lacking this family history.</p><p><strong>Methods: </strong>A pretested survey was administered between January-February 2021 to a U.S. sample of 3,062 parents/caregivers of children born since the NIAID Addendum guidelines. Survey-weighted chi-square statistics and logistic regression models tested the independence of key variables across strata of interest before and after covariate adjustment.</p><p><strong>Results: </strong>Peanut, almond, shellfish, and other tree nuts are more likely to be introduced to children with one or more food-allergic caregivers. Respondents with food-allergic parents (39.3%) and siblings with FA (35.8%) were more familiar with the 2017 NIAID guidelines compared to parents (12.9%) and siblings without FA (12.7%).</p><p><strong>Conclusion: </strong>Findings suggest that respondents with food-allergic parents and siblings are more likely to have many of the most prevalent allergens introduced at younger ages, which could be due to knowledge related to the NIAID-sponsored guidelines and other national guidance, but that even among these higher-risk families overall rates of \"early\" introduction during infancy still remain relatively low.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1562667"},"PeriodicalIF":3.3,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life effectiveness of once-daily single-inhaler triple therapy (FF-UMEC-VI) after switching from dual therapy (ICS-LABA) in patients with symptomatic asthma: trelegy ellipta for real asthma control study.","authors":"Yoshitomo Kushima, Yasuo Shimizu, Ryo Arai, Kazuyuki Chibana, Yuka Shimizu, Masahiro Amagai, Akihiro Takemasa, Naoya Ikeda, Meitetsu Masawa, Atsushi Kushima, Hiroaki Okutomi, Yusuke Nakamura, Rinna Tei, Yuki Ando, Nana Yazawa, Yuto Goto, Yasuo Haruyama, Tatsuo Yukawa, Seiji Niho","doi":"10.3389/falgy.2025.1537501","DOIUrl":"10.3389/falgy.2025.1537501","url":null,"abstract":"<p><strong>Introduction: </strong>A well-designed, protocol-driven randomized controlled trial (RCT) has demonstrated the efficacy of fluticasone furoate-umeclidinium-vilanterol (FF-UMEC-VI) in patients with asthma, but there is a lack of real-world data that can be used to translate the results of the RCT into clinical practice. This study evaluated the efficacy of switching the therapy from inhaled corticosteroid-long-acting β2-agonists (ICS-LABAs) to FF-UMEC-VI at the equivalent corticosteroid dose in a real-world setting.</p><p><strong>Methods: </strong>A prospective, three-month, open-label, parallel-group, switching therapy trial was performed in patients with symptomatic asthma under routine management. Patients receiving low-to-medium doses of ICS-LABAs were switched to FF-UMEC-VI (100-62.5-25 µg, once daily) (T100 group), and patients receiving a high dose of ICS-LABAs were switched to FF-UMEC-VI (200-62.5-25 µg, once daily) (T200 group). The primary outcome was the change from baseline in forced expiratory volume in 1 s (ΔFEV1) at week 12, and the secondary outcomes were the improvement in fractional exhaled nitric oxide (FeNO), the asthma symptoms evaluated using the asthma control test (ACT), and the cough severity evaluated using the visual analog scale (VAS).</p><p><strong>Results: </strong>Thirty-five patients were switched to T100, and thirty patients were switched to T200. The ΔFEV1 was improved by more than 100 ml at 8 weeks after switching in both groups (T100, 110.4 ± 39.8 ml; T200, 117.1 ± 39.8 ml) (<i>p</i> < 0.05) but slightly decreased at 12 weeks. ACT also improved by more than 3 points at 8 weeks after switching and was maintained to 12 weeks in both groups (<i>p</i> < 0.05). Patients with ACT scores of <20 (i.e., poor control) before switching showed a greater improvement in the symptoms during T100 therapy, and 92% had reached an ACT score of >20 (i.e., good control). FeNO in the T100 group was decreased at 4 weeks (<i>p</i> < 0.05). Cough VAS also significantly decreased but did not reach a minimal clinically important difference.</p><p><strong>Conclusions: </strong>In patients with symptomatic asthma showing insufficient control, an improvement in the asthma symptoms was observed after switching to FF-UMEC-VI at the equivalent corticosteroid dose, accompanied by an improvement in FEV1.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1537501"},"PeriodicalIF":3.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Milk ladder: Who? When? How? Where? with the lowest risk of reaction.","authors":"Betul Buyuktiryaki, Ozge Soyer, Duygu Yazici, Gulbin Bingol, Ceren Can, Hikmet Tekin Nacaroglu, Aysen Bingol, Ebru Arik Yilmaz, Metin Aydogan, Cansin Sackesen","doi":"10.3389/falgy.2025.1576302","DOIUrl":"https://doi.org/10.3389/falgy.2025.1576302","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/falgy.2024.1516774.].</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1576302"},"PeriodicalIF":3.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scratching the surface: biomarkers and neurobiomarkers for improved allergic contact dermatitis management.","authors":"Akimi Sasaki, Manuel Sargen, Anish R Maskey, Xiu-Min Li","doi":"10.3389/falgy.2025.1564528","DOIUrl":"10.3389/falgy.2025.1564528","url":null,"abstract":"<p><p>Allergic contact dermatitis (ACD), also known as allergic eczema, is a common inflammatory skin disorder that affects millions of Americans and imposes significant physical, psychological, and economic burdens. Differentiating ACD from other forms of dermatitis remains a challenge, with patch testing as the gold standard. Despite its utility, patch testing can lack diagnostic accuracy, highlighting the importance of molecular biomarkers to refine diagnosis and treatment. Advances in transcriptomics and machine-learning have enabled the identification of biomarkers involved in ACD, such as loricrin (LOR), ADAM8, CD47, BATF, SELE, and IL-37. Moreover, biomarkers such as LOR, NMF, and TEWL, may have prognostic value in evaluating therapeutic response. Emerging neurological biomarkers (neurobiomarkers), including IL-31 and TRPV1, target pathways involved in the pruritic and inflammatory responses, offering novel therapeutic targets as well. This mini review summarizes current ACD treatments, biomarkers for targeted therapies, and emphasizes the role of neurobiomarkers in ACD treatment. Additional research on the validity of the therapeutic potential of these biomarkers is necessary to improve ACD treatment and outcomes.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1564528"},"PeriodicalIF":3.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of omalizumab after discontinuation: a retrospective single-center observational study in children with severe asthma.","authors":"Simone Foti Randazzese, Cecilia Lugarà, Francesca Galletta, Giovanni Pioggia, Giuseppe Crisafulli, Lucia Caminiti, Sebastiano Gangemi, Paolo Ruggeri, Sara Manti","doi":"10.3389/falgy.2025.1529624","DOIUrl":"10.3389/falgy.2025.1529624","url":null,"abstract":"<p><strong>Introduction: </strong>Several trials documented safety and efficacy of omalizumab, but there are a few data about its effects after discontinuation. This study aims to evaluate the maintenance of efficacy of omalizumab in pediatric asthmatic patients one year after its suspension.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 17 subjects aged 6-18 years, divided into two groups: Group A (9 patients) who discontinued omalizumab after 18 months, and Group B (8 patients) who continued the therapy. Data on respiratory function (FEV1%), the number of exacerbations, need for hospitalizations, use of oral corticosteroids, and Asthma Control Test (ACT) scores were collected and analyzed at three time points: baseline (T0), after 18 months of treatment (T1), and 36 months (T2).</p><p><strong>Results: </strong>In Group A, significant differences were observed between T0 and T1, and T1 and T2, in FEV1% values, the number of exacerbations, the need for oral corticosteroids, and ACT scores. Group B showed significant differences in these parameters over time, with a notable reduction in exacerbations and improvement in ACT scores. The comparative analysis revealed that Group B had a higher number of exacerbations compared to Group A at T0 and greater use of oral cortico-steroids at T1. By T2, Group A had a higher ACT score than Group B at T0, whereas Group B showed higher ACT scores at T2 compared to Group A.</p><p><strong>Discussion: </strong>The study confirmed the efficacy and safety of omalizumab, with its benefits persisting one year after treatment discontinuation in terms of lung function, reduction in exacerbations, decreased need for oral corticosteroids, and improved quality of life. Further research is necessary.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1529624"},"PeriodicalIF":3.3,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}